Gain Therapeutics マネジメント
マネジメント 基準チェック /24
Gain Therapeuticsの CEO はGene Mackで、 Jun2024年に任命され、 の在任期間は 1.92年です。 の年間総報酬は$ 1.47Mで、 34.1%給与と65.9%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.034%を直接所有しており、その価値は$ 26.21K 。経営陣と取締役会の平均在任期間はそれぞれ2.2年と5.3年です。
主要情報
Gene Mack
最高経営責任者
US$1.5m
報酬総額
| CEO給与比率 | 34.08% |
| CEO在任期間 | 1.9yrs |
| CEOの所有権 | 0.03% |
| 経営陣の平均在職期間 | 2.2yrs |
| 取締役会の平均在任期間 | 5.3yrs |
経営陣の近況
Recent updates
分析記事 • 22h
Gain Therapeutics expands ‘compelling’ evidence base for Parkinson’s candidate
Gain Therapeutics’ Parkinson’s candidate GT-02287 showed durable clinical stability and biomarker improvements in extended Phase 1b data.分析記事 • May 22
3 Parkinson's Biotech Stocks Analysts Think Are Wildly Mispriced
Most biotech stocks working towards a treatment for Parkinson's are already carrying a premium price. These three sit further off the radar, and analysts think the market has them badly wrong.分析記事 • May 05
3 US Biotechs Developing Parkinson’s Therapies
Global markets may be dealing with inflation, shifting rate expectations, and energy volatility, but companies tackling long-term health challenges like Parkinson’s disease are still pushing ahead.
新しいナラティブ • Apr 01
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Seeking Alpha • Nov 07
Gain Therapeutics: Valuation Remains Low In Light Of Recently Reported Functional Improvement In PD Patients
Summary Gain Therapeutics achieved functional improvement in Parkinson’s patients with GT-02287 in its Phase 1b trial, notably improving MDS-UPDRS Part III motor scores. GT-02287’s mechanism addresses GCase misfolding earlier in the disease process, potentially offering superior efficacy versus competitors. GANX’s $66 million market cap is seen as deeply undervalued given positive trial data, large market potential, and higher-value biotech acquisitions. I reiterate a Strong Buy rating for GANX. Read the full article on Seeking AlphaSeeking Alpha • Dec 31
Gain Therapeutics: Parkinson's Drug Candidate GT-02287 Keeps Racking Up Good Results
Summary Gain Therapeutics' GT-02287 shows promising efficacy and safety data, targeting both idiopathic and GBA1 Parkinson’s disease, with potential for substantial market impact and investor gains. The drug's ability to restore GCase function and its positive preclinical and Phase 1 results highlight its potential as a best-in-class treatment. Gain's aggressive development strategy and strong data sharing indicate confidence, with Phase 1b trial results expected by mid-2025, potentially increasing the company's valuation. Read the full article on Seeking AlphaSeeking Alpha • May 29
Gain Therapeutics: Phase 1 Readout Awaits For Parkinson's Drug With Great Potential
Summary Gain Therapeutics, Inc.'s drug candidate GT-02287 has best-in-class potential to slow or stop disease progression in Parkinson's disease. Gain is progressing at an impressive speed through its Phase 1 trial. Drug discovery engine Magellan, which had already generated a Phase 3 drug in the past, may be overlooked by investors. Gain Therapeutics is considerably undervalued compared to peers and recent acquisition targets in the neurodegenerative space. Read the full article on Seeking AlphaSeeking Alpha • Jan 12
Gain Therapeutics: The Case For GCase In Parkinson's And Buyout Potential
Summary Gain Therapeutics' drug candidate GT-02287 targets GCase and lysosomal dysfunction, potentially succeeding where others may fail. The company's AI-driven drug discovery engine has generated several targets across different diseases. GT-02287 is currently in a Phase 1 trial for GBA-1-PD, and Gain will add further preclinical data in February to its already interesting preclinical dataset. Gain's stock has been performing well, and similarities with a recent acquisition of Caraway Therapeutics by Merck may confirm its undervaluation. Read the full article on Seeking AlphaSeeking Alpha • Sep 20
Gain Therapeutics appoints CEO
Biotechnology company Gain Therapeutics (NASDAQ:GANX) said COO Matthias Alder has been appointed CEO, effective immediately. Alder, who was also appointed to the company's board, succeeds Eric Richman. The size of the company's board is now increased to eight members. Richman will continue to serve as a board member and as a senior advisor. Source: Press ReleaseSeeking Alpha • Oct 27
Gain Therapeutics: Shares Of Enzyme Therapy/Neurodegeneration Specialist Look Like A Surprisingly Good Value
Gain Therapeutics has a market cap of just $84m. The biotech is developing small molecules to treat rare genetic diseases. The company uses a proprietary drug discovery engine, SEE-Tx, which targets allosteric binding sites, and misfolded proteins - approaches previously validated either by trial data or major investment. Gain has not yet had an IND accepted by the FDA, but targets include GM1 Gangliosidosis, Parkinson's, and Gaucher Disease. There are areas of high unmet need and competitive fields, but Gain does at least have some promising preclinical data. The $7 per share entry point feels cheap to me, with numerous upcoming catalysts, an experienced management team and Board, and oral availability all plus points.Seeking Alpha • Aug 19
Gain Therapeutics: A True Revolution In Drug Development At Venture-Like Pricing
Gain’s cutting-edge precision medicine platform and novel compounds enable therapeutic access to previously undruggable targets. Public investors can access this disruptive technology at a venture-like valuation. A clean balance sheet funds the business until H2 2023, with multiple value inflections expected. Management has a track record of creating value through pharma partnerships and exits. Approaching top-line data for lead compound in GBA1 Parkinson’s has game-changing potential.CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$21m |
| Dec 31 2025 | US$1m | US$500k | -US$20m |
| Sep 30 2025 | n/a | n/a | -US$19m |
| Jun 30 2025 | n/a | n/a | -US$19m |
| Mar 31 2025 | n/a | n/a | -US$21m |
| Dec 31 2024 | US$991k | US$271k | -US$20m |
報酬と市場: Geneの 総報酬 ($USD 1.47M ) は、 US市場 ($USD 624.15K ) の同規模の企業の平均を上回っています。
報酬と収益: Geneの報酬は増加しましたが、会社は利益を上げていません。
CEO
Gene Mack (51 yo)
1.9yrs
在職期間
US$1,467,139
報酬
Mr. Gene Mack, M.B.A. is President, Chief Executive Officer & Director of Gain Therapeutics, Inc. from January 06, 2025 and was its Chief Financial Officer since April 8, 2024 until January 06, 2025 and wa...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Chairman & Founder | 9.3yrs | US$93.15k | 2.18% $ 1.7m | |
| President | 1.9yrs | US$1.47m | 0.034% $ 26.2k | |
| Senior VP of Finance & Principal Financial Officer | 1.3yrs | US$345.07k | 0.079% $ 61.0k | |
| Senior Vice President of Technical Operations | no data | データなし | データなし | |
| Senior Vice President of Research | 3.9yrs | データなし | データなし | |
| Chief Medical Officer | 2.2yrs | データなし | データなし |
2.2yrs
平均在職期間
51yo
平均年齢
経験豊富な経営陣: GANXの経営陣は 経験豊富 であると考えられます ( 2.2年の平均在職年数)。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Chairman & Founder | 9.3yrs | US$93.15k | 2.18% $ 1.7m | |
| President | 1.3yrs | US$1.47m | 0.034% $ 26.2k | |
| Independent Director | 5.3yrs | US$80.15k | 0% $ 0 | |
| Member of Clinical Advisory Board | no data | データなし | データなし | |
| Independent Director | 5.3yrs | US$63.15k | 0% $ 0 | |
| Independent Director | 6.3yrs | US$76.65k | 0% $ 0 | |
| Independent Director | 7yrs | US$78.65k | 0.070% $ 54.6k | |
| Independent Director | 5.3yrs | US$68.15k | 0% $ 0 | |
| Member of Clinical Advisory Board | 1.3yrs | データなし | データなし | |
| Member of Clinical Advisory Board | 1.3yrs | データなし | データなし | |
| Member of Clinical Advisory Board | 1.3yrs | データなし | データなし |
5.3yrs
平均在職期間
69.5yo
平均年齢
経験豊富なボード: GANXの 取締役会 は 経験豊富 であると考えられます ( 5.3年の平均在任期間)。
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/27 04:56 |
| 終値 | 2026/05/27 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Gain Therapeutics, Inc. 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。7
| アナリスト | 機関 |
|---|---|
| Mayank Mamtani | B. Riley Securities, Inc. |
| Thomas Shrader | BTIG |
| Raghuram Selvaraju | H.C. Wainwright & Co. |